New Drug Assignments and Reassignments for 2010
- Tocilizumab (Actemra®); Genentech; for the treatment of rheumatoid arthritis - AHFS Class: 92:36 "Disease Modifying Antirheumatic Agents" (Jan, 2010)
- Dalfampridine (Ampyra®); Acorda; for the improvement of walking in patients with multiple sclerosis - AHFS Class: 92:92 "Other Misc Therapeutic Agents" (Jan, 2010)
- Liraglutide (Victoza®); Novo Nordisk; for the treatment of type 2 diabetes mellitus - AHFS Class: 68:20.06 "Incretin Mimetics" (Jan, 2010)
- Collagenase clostridium histolyticum (Xiaflex®); Auxilium; orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord - AHFS Class: 44:00 "Enzymes" (Feb, 2010)
- Velaglucerase alfa (VPRIV®); Shire; for treatment of type 1 Gaucher disease - AHFS Class: 44:00 "Enzymes" (Feb, 2010)
- Desirudin (Iprivask®); Canyon; for prophylaxis of deep vein thrombosis in patients undergoing hip replacement surgery - AHFS Class: 20:12.04.12 "Direct Thrombin Inhibitors" (launched: Mar, 2010)
- Polidocanol (Asclera®); BioForm Medical; for treatment of small vericose veins - AHFS Class: 24:16 "Sclerosing Agents" (Mar, 2010)
- Carglumic acid (Carbaglu®); Orphan Europe; for treatment of N-acetylglutamate synthase (NAGS) deficiency which results in elevated blood levels of ammonia - AHFS Class: 40:10 "Ammonia Detoxicants" (Mar, 2010)
- Guanfacine (Intuniv®); Shire; for treatment of ADHD in pediatric patients - AHFS Class: 28:92 "Misc CNS Agents" (May, 2010)
- Sipuleucel-T (Provenge®); Dendreon; immunotherapy for prostate cancer - new AHFS Class: 26:00 "Cellular Therapy" (July, 2010)
- Conivaptan (Vaprisol®) and Tolvaptan (Samsca®); reassigned from 40:28.92 to new AHFS Class: 40:28.28 "Vasopressin Antagonists" (July, 2010)
AHFS Classification Changes for 2010
The following table describes changes to the AHFS Pharmacologic-Therapeutic Classification© that went into effect
with the publication of the 2010 edition of AHFS Drug Information® (February 1, 2010). This is only a partial listing
of the AHFS PTC. The full classification system, along with a list of drugs covered in AHFS DI and their
corresponding classes, is available in the printed edition and is available electronically in a separate file. Please contact
the ASHP Marketing and Sales Office for licensing information at
301-664-8757 or marketing@ashp.org.
| AHFS Class |
Retired |
Change Description |
12:16.04
|
- |
New classification (α-Adrenergic Blocking Agents) |
12:16.04.04
|
- |
New classification (Non-selective α-Adrenergic Blocking Agents) |
12:16.04.08
|
- |
New classification (Non-selective α1-Adrenergic Blocking Agents) |
12:16.04.12
|
- |
New classification (Selective α1-Adrenergic Blocking Agents) |
12:16.08
|
- |
New classification (β-Adrenergic Blocking Agents) |
12:16.08.04
|
- |
New classification (Non-selective β-Adrenergic Blocking Agents) |
12:16.08.08
|
- |
New classification (Selective β-Adrenergic Blocking Agents) |
28:40
|
- |
New classification (Fibromyalgia Agents) |
All material distributed as part of AHFS Drug Information is copyrighted. Reproduction, storage on a retrieval system, or
transmission of this material or any part thereof in any form or by any means without the express written permission of the
American Society of Health-System Pharmacists is prohibited.
Please contact ASHP eHealth Solutions Division at +1 (301) 664-8647 for more detailed information.
© Copyright, 2010, American Society of Health-System Pharmacists, Inc. All Rights Reserved.